HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.
暂无分享,去创建一个
Charles C Wykoff | Adrian L Harris | A. Harris | C. Wykoff | P. Ratcliffe | P. Murray | H. Sowter | S. Mandriota | P. Maxwell | E. Maher | N. Morgan | Neil V Morgan | Eamonn R Maher | Paul G Murray | Patrick H Maxwell | K. Turner | D. R. Davies | Peter J Ratcliffe | Heidi M Sowter | Stefano J Mandriota | Kevin J Turner | David R Davies | D. Davies | S. Mandriota
[1] R. Waldherr,et al. Co-expression of cytokeratin and vimentin intermediate-sized filaments in renal cell carcinomas , 2004, Virchows Archiv A.
[2] P. Pandolfi,et al. Mouse models for multistep tumorigenesis. , 2001, Trends in cell biology.
[3] S. McKnight,et al. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.
[4] Michael I. Wilson,et al. C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.
[5] J. M. Arbeit,et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. , 2001, Genes & development.
[6] S. White,et al. HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[7] P. Ratcliffe,et al. Activation of the HIF pathway in cancer. , 2001, Current opinion in genetics & development.
[8] M. Ivan,et al. HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.
[9] Michael I. Wilson,et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.
[10] W. Kaelin,et al. The von Hippel-Lindau tumor suppressor gene. , 2001, Experimental cell research.
[11] K. Kinzler,et al. Top-down morphogenesis of colorectal tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Klausner,et al. Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[13] P. Porter,et al. Molecular markers of tumor initiation and progression. , 2001, Current opinion in genetics & development.
[14] T. Mak,et al. Animal models of tumor-suppressor genes. , 2001, Annual review of genetics.
[15] P H Watson,et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.
[16] R. Burk,et al. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis , 2000, Oncogene.
[17] A. Harris,et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .
[18] G. Semenza,et al. Hypoxia, Clonal Selection, and the Role of HIF-1 in Tumor Progression , 2000, Critical reviews in biochemistry and molecular biology.
[19] A. Knudson,et al. Chasing the cancer demon. , 2000, Annual review of genetics.
[20] C. Wykoff,et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.
[21] E. Tschachler,et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. , 1999, The American journal of pathology.
[22] M. Wei,et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[23] W. Kaelin,et al. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[24] R. Burk,et al. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] E. Paal,et al. A clinicopathologic and immunohistochemical study of ten pancreatic lymphangiomas and a review of the literature , 1998, Cancer.
[26] D. Louis,et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. , 1998, Molecular cell.
[27] R. Klausner,et al. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Gassmann,et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.
[29] E. Stanbridge,et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.
[30] Bert Vogelstein,et al. Gatekeepers and caretakers , 1997, Nature.
[31] D. Charnock-Jones,et al. Hepatocyte growth factor/scatter factor and its receptor c-met: localisation and expression in the human placenta throughout pregnancy. , 1996, The Journal of endocrinology.
[32] K. Kinzler,et al. Lessons from Hereditary Colorectal Cancer , 1996, Cell.
[33] R. Motzer,et al. Renal-cell carcinoma. , 1996, The New England journal of medicine.
[34] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[35] S. Jacobs,et al. Transforming growth factor-alpha expression in human renal cell carcinoma: TSG-α expression in renal cell carcinoma , 1996 .
[36] B. Ebert,et al. Hypoxia and Mitochondrial Inhibitors Regulate Expression of Glucose Transporter-1 via Distinct Cis-acting Sequences (*) , 1995, The Journal of Biological Chemistry.
[37] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[38] M. Ferguson-Smith,et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. , 1994, Human molecular genetics.
[39] J. Brooks,et al. Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.
[40] M. D. de Broe,et al. Hyperplasia, hypertrophy, and phenotypic alterations in the distal nephron after acute proximal tubular injury in the rat. , 1994, Laboratory investigation; a journal of technical methods and pathology.
[41] J. Gnarra,et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.
[42] E. Manseau,et al. Vascular permeability factor mRNA and protein expression in human kidney. , 1992, Kidney international.
[43] S. Pastoreková,et al. A novel quasi-viral agent, MaTu, is a two-component system. , 1992, Virology.
[44] T. Ezaki,et al. A new approach for identification of rat lymphatic capillaries using a monoclonal antibody. , 1990, Archives of histology and cytology.
[45] P. Yen,et al. In situ hybridization of prepro-epidermal growth factor mRNA in the mouse kidney. , 1989, The American journal of physiology.
[46] M. Birnbaum,et al. Growth factors rapidly induce expression of the glucose transporter gene. , 1988, The Journal of biological chemistry.
[47] R. D. Marshall,et al. Localization of Tamm-Horsfall glycoprotein in the human kidney using immuno-fluorescence and immuno-electron microscopical techniques. , 1981, Journal of anatomy.
[48] R. C. Nairn,et al. Renal tubular antigens in kidney tumors , 1972, Cancer.